Drugs · acquisition-cost intelligence
Memantine and Donepezil Hydrochlorides Extended-release
Memantine and Donepezil· ingredient donepezilAnticholinesterases· DONEPEZIL HYDROCHLORIDE 10 mg/1; MEMANTINE HYDROCHLORIDE 14 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1; MEMANTINE HYDROCHLORIDE 21 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1; MEMANTINE HYDROCHLORIDE 28 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1; MEMANTINE HYDROCHLORIDE 7 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$11.97
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other donepezil products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Donepezil | $0.04571 | −$11.93 |
| Aricept | $0.04761 | −$11.92 |
| Donepezil hydrochloride | $0.76174 | −$11.21 |
Medicare Part D coverage · CY2026
On 142 plan formularies · typical tier 3
Prior auth 28% · Step therapy 4% · Quantity limit 25% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.